Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRE-11: Continuous vs Intermittent Cetuximab + FOLFIRI in mCRC
NCT07004413Phase 3Not yet recruiting
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Modality
- Nanoparticles, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of KL-140, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, folinic acid, fluorouracil in colorectal cancer (CRC), sponsored by Charité – Universitätsmedizin Berlin. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
KL-140irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfolinic acidfluorouracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07004413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07004413.